NordiQC data: Antibody selection, protocols and controls

85 01 12.889

The generel module

Tanya Julio Histotechnologist Pathology department Aarhus University Hospital, DK

491.48 99.89 • 25.51%



Primary panel for the unknown primary tumour

<text>

Janei IOI		CD45	Pan-CK	S100	Vimentin
own					
tumour	Haematolymphoid neoplasms	+/(-)	-/(+)	-/(+)	+/(-)
tumour	Epithelial neo vi isms	-	+/(-)	-/+	-/+
asy as	neoothelial neoplasms	-	+	-	+
Is it as easy as	mesenchymal and neuronal neoplasms	-	-/(+)	-/+	+
	non-neuronal neuroephithelial neoplasms	-	-/(+)	+	+
	Germ cell neoplasms	-	-/+	-/+	+



100%

Pass rate


80%

60%

Run 59 2020

CD45

Run 15 2005



Run 37 2013

Number of participants — Pass rate

CD45 performance in NordiQC assessments

76% are using the mAb clone **2B11+PD7/26**

And it is a real Ready-touse!!



Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clones 2B11+PD7/26 GA751 (VRPS) ³	23	Agilent/Dako	23	0	0	0	100%	100%
mAb clones 2B11+PD7/26 GA751 (LMPS)⁴	27	Agilent/Dako	23	4	0	0	100%	85%
mAb clones 2B11+PD7/26 IR/IS751 (VRPS) ³	6	Agilent/Dako	6	0	0	0	100%	100%
mAb clones 2B11+PD7/26 IR/IS751(LMPS)⁴	18	Agilent/Dako	17	0	0	1	94%	94%
mAb clones 2B11+PD7/26 760-4279 (VRPS) ³	7	Ventana/Roche	7	0	0	0	100%	100%
mAb clones 2B11+PD7/26 760-4279 (LMPS)⁴	36	Ventana/Roche	32	4	0	0	100%	89%
mAb clone X16/99 PA0042 (VRPS) ³	5	Leica Biosystems	3	1	1	0	80%	60%
mAb clone X16/99 PA0042 (LMPS)⁴	4	Leica Biosystems	1	3	0	0	-	-
mAb clone RP2/18 760-2505 (VRPS) ³	3	Ventana/Roche	0	0	2	1	-	-
mAb clone RP2/18 760-2505 (LMPS) ⁴	45	Ventana/Roche	36	6	3	0	93%	80%
Total	296		232	45	15	4	-	
Proportion			79%	15%	5%	1%	94%	

Only a cut out of table 1





	m		from 1	Table 1. Re	commended Staining	Protocols for CONFIRM	anti-CD45, LCA (RP2/18)
	ĽĽ	HATAR	NUU / /	Proce	edure Type	Platform	or Method
	1	SAYING	Ð			NexES IHC	BenchMark Series
	1	Chunc		Depar	raffinization	Off Line	Selected
		6	Table 3. Recommended signal Primary Antibody with OptiV instruments.		or CONFIRM anti-CE tection Kit on Bench		None required
1		(C)			Method		None required
			Procedure Type	GX	ХТ	ULTRA or ULTRA PLUS ^a	Approximately 16 minutes, 37° C
			Deparaffinization	Selected	Selected	Selected	Optional
VOID		NGUAGE J	Cell Conditioning	CC1,	CC1,	ULTRA CC1,	Optional
	Property in the local division of	GIBBERIS	(Antigen Unmasking)	16 minutes	24 minutes	24 minutes, 100°C	Hematoxylin II, 2 to 4 minutes
			Pre-Primary Peroxidase Inhibitor	Selected	Selected	Selected	Bluing, 2 to 4 minutes
mAb clone RP2/18 760-2505 (VRPS) ³	3	Ventana/Roc	Antibody (Primary)	4 minutes, 37°C	4 minutes, 37°C	4 minutes, 36°C	
			Counterstain		Hematoxylin II, 4 m	ninutes	
mAb clone RP2/18 760-2505 (LMPS) ⁴	45	Ventana/Roc	Post Counterstain		Bluing, 4 minut	es	
700 2000 (EMPO)		_					



Controls – Tonsil

RP2/18 Ventana RTU






All lymphocytes (B- and T- cells) and histocytes must display a strong distinct membranous staining reaction. Squamous epithelial cells should be negative.



.... And Liver!


CD45, RP2/18 Ventana RTU



The Kupffer cells should show a weak to moderate staining reaction whereas hepatocytes must be negative.



CK-PAN



Participants, n= ----Pass rate %



			Ready-To	-Use antibo	odies	n	Vendo	r		Optimal	Good	Borderline	Poor	Suff.1	OR. ²
			mAb clon AE1/AE3 IR053 (N	3		13	Dako/	Agilent		12	-	-	1	92%	92%
Table 2. Proportion the four main IHC		l results for	CK-PAN us	ing the mA	b clone co	ocktail	AE1/A	E3 as conc	entrate on	10	2	2	-	86%	71%
Concentrated antibodies	Dako/A Autost		Dako/A Om	_	Venta Benchl L	-			ica I / Max	27	1	2	1	90%	87%
mAb clone	TRS pH 9.0 5/9**	TRS pH 6.1	TRS pH 9.0 6/6	TRS pH 6.1	CC1 pH 8.5 36/62		C2 pH 6.0	BERS2 pH 9.0 0/12	BERS1 pH 6.0	17	1	-	-	100%	94%
AE1/AE3 MAb clone BS5 * Antibody concentrati	(56%) 0/2	- - listed above. H	100% 1/1	- - d detection ki	(58%) 2/3	rovided	- - by the y	(0%) 3/6	0/3 1/1	11	8	4	2	76%	44%
systems. ** Number of optimal			es using this b	uffer.				-,		29	19	10	11	70%	42%
			mAb clon AE1/AE3 PA0909		.mps)*	2	Leica/	Novocastra		 -	1	1	-	-	-
			mAb clon AE1/AE3 PA0094			5	Leica/	Novocastra		1	3	1	-	80%	20%
			mAb clon AE1/AE3 PA0012			3	Leica/	Novocastra		-	3	-	-	-	-
			Total Proportio	n		326				168 52%	75 23%	47 15%	36 11%	- 75%	

		HIER OptiView	
	44%	42%	
	76%	70%	
	2	11	
	4	10	
	8	19	Charles and Charles
	11	29	
HIER+P3 OptiView	Ventana/Roche	Ventana/Roche	
Sol and a sol	25	69	
) ³		
	mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (VRPS) ³	mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (LMPS) ⁴	Photos of Clear cell renal cell carcinoma
	01		

Sec. © NordiQC

P1 OptiView

mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (VRPS) ³	25	Ventana/Roche	11	8	4	2	76%	44%	
mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (LMPS) ⁴	69	Ventana/Roche	29	19	10	11	70%	42%	



Table 4. Pass rates for antibody cocktails combined with epitope retrieval methods in nine NordiQC runs

Pa	ss rate for	compiled d	ata from ru	ın 15, 20, 2	4, 30, 36, 4	41, 47, 54 8	£ 58	
	То	otal	H	ER	Prote	olysis	HIER + p	roteolysis
	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient
mAb AE1/AE3	1145	836 (73%)	1075	826 (77%)	49	6 (12%)	9	3 (33%)
mAb AE1/AE3/5D3	48	42 (88%)	47	42 (89%)	1	0	0	0
mAb AE1/AE3/PCK26	361	219 (61%)	48	22 (46%)	48	3 (6%)	258	192 (74%)
mAb MNF116	111	31 (28%)	53	9 (17%)	48	22 (46%)	9	2 (22%)



Table 2. Recommended staining protocol for Anti-Pan Keratin (AE1/AE3/PCK26)

 antibody with *ultra*View Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

Procedure Ture		Method	
Procedure Type	GX	ХТ	ULTRA
Deparaffinization	Selected	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1, Mild	CC1, Mild	ULTRA CC1 36 minutes, 95°C
Antibody (Primary)	4 minutes, 37°C	8 minutes, 37°C	8 minutes, 36°C
*ultraBlock step using VENTANA Antibody Diluent with Casein		4 minutes	
Counterstain	н	ematoxylin II, 4 minu	tes
Post Counterstain		Bluing, 4 minutes	

*Use of VENTANA Antibody Diluent with Casein at the ultraBlock step is recommended to reduce staining on smooth muscle.

Table 2. Recommended staining protocol for Anti-Pan Keratin (AE1/AE3/PCR20) antibody with *ultra*View Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

		Method	
Procedure Type	GX	ХТ	ULTRA or ULTRA PLUS ^a
Deparaffinization	Selected	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1, Mild	CC1, Mild	ULTRA CC1 36 minutes, 95°C
Enzyme (Protease)		Protease 3, 4 minute	s
Antibody (Primary)	4 minutes, 37°C	8 minutes, 37°C	8 minutes, 36°C
ultraBlock step using VENTANA Antibody Diluent with Casein ^b		4 minutes	
Counterstain	Н	ematoxylin II, 4 minu	tes
Post Counterstain		Bluing, 4 minutes	


Control -Esophagus

All squarmous epithelial cells throughout all the cell layers must show a strong distinct cytoplasmic staining reaction due to expression of HMW-CK types 5 and 14. Smooth muscle cells in vessels and in muscularis mucosa in esophagus will typically show a weak to moderate patchy cytoplasmic staining.



And Liver


It is crucial that the vast majority of the hepatocytes (expression only a limited amount of the primary LMW CK types 8 and 18) show an at least moderate, distinct cytoplasmic and membranous staining reaction. No staining should be seen in stromal cells in the liver.



AE1/AE3/PCK26 RTU Ventana



S100



S100 performance in NordiQC assessments

Back in 2003 the main problem among the non-sufficient protocols was omission of HIER or use of proteolytic pretreatment, and guess what – it still is!!



Table 5. Pass rates for S100 antibody combined with epitope retrieval methods in the last three NordiQC runs

	_		Pass rate	for compil	ed data fi	<u>om run 45</u>	5, <u>50 & 59</u>			
	То	tal	HI	ER	Prote	olysis		R + olysis	No pretr	eatment
	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient
mAb 4C4.9	137	80 (58%)	110	71 (65%)	4	0	2	1	21	8 (38%)
pAb NCL-L- S100p	30	18 (60%)	21	14 (67%)	6	2 (33%)	0	0	3	2
pAb Z0311	494	417 (84%)	444	386 (87%)	26	15 (58%)	3	2	21	14 (67%)
pAb 760- 2523	97	68 (70%)	82	62 (76%)	2	1	0	0	13	5 (39%)
Total	758	583 (77%)	657	533 (81%)	38	18 (47%)	5	3	58	29 (50%)

Controls

Only Z0311

In the tonsil, interfollicular dendritic cells and Langerhans cells of the squamous epithelium, must display a moderate to strong staining intensity whereas the follicular dendritic cell meshwork of the germinal centres should show an at least weak to moderate nuclear and cytoplasmic staining reaction.




Appendix

Virtually all adipocytes and Schwann cells of peripheral nerves, must show an as strong as possible nuclear and cytoplasmic staining reaction without any staining reaction of the smooth muscle or epithelial cells.



In addition

All neoplastic cells should show a strong nuclear and cytoplasmic staining reaction in the malignant melanoma





The clone Z0311 which was used by 57% both as concentrate and RTU is now terminated from vendor as a concentrate.


SOX10

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone 4C4.9	2	Thermoscientific Immunologic Cell Marque Diagnostic BioSystems DCS BioCare Medical Zytomed Systems Zeta Corporation	2	5	2	2	63%	18%
pAb Z0311 ⁵	100	Agilent/Dako	55	27	15	3	82%	55%
pAb NCL-L-S100p	8	Leica/Novocastra	1	4	2	1	62%	13%
Readv-To-Use antibodies			l				Suff. ¹	OR. ²
mAb clone 4C4.9 790-2914 (VRPS) ³	4	Roche/Ventana	-	4	-	-	-	-
mAb clone 4C4.9 790-2914 (LMPS) ⁴	33	Roche/Ventana	9	15	8	1	73%	27%
pAb 760-2523 (VRPS) ³	11	Roche/Ventana	3	7	1	-	91%	27%
pAb 760-2523 (LMPS) ⁴	32	Roche/Ventana	8	15	9	-	72%	25%
pAb IS/IR504 (VRPS) ³	6	Agilent/Dako	4	2	-	-	100%	67%
pAb IS/IR504 (LMPS) ⁴	19	Agilent/Dako	14	4	1	-	95%	74%
pAb GA504 (VRPS) ³	29	Agilent/Dako	28	1	-	-	100%	97%
pAb GA504 (LMPS) ⁴	17	Agilent/Dako	13	3	1	-	94%	77%
pAb PA0900 (VRPS) ³	3	Leica/Novocastra	-	-	3	-	-	-
pAb PA0900 (LMPS) ⁴	10	Leica/Novocastra	1	6	3	-	70%	10%
Total	299		142	102	48	7	-	
Proportion			48%	34%	16%	2%	82%	

Total	250	167	63	16	4	-	
Proportion		67%	25%	6%	2%	92%	



Vimentin



Tonsil is out





Fig. 1a

Optimal VIM staining of the tonsil using the mAb clone V9 carefully calibrated after HIER. The intraepithelial lymphocytes, the mantle zone B-cells and the germinal centre macrophages show a strong and distinct staining. No staining is is seen in the squamous epithelial cells.



According to the new guidelines provided by the International Ad Hoc Expert Committee (Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18.)



Pancreas: Epithelial cells of exocrine acini must show a weak but distinct cytoplasmic staining reaction. Liver: Virtually all Kupffer cells must show an at least moderate and distinct cytoplasmic staining reaction, while endothelial cells of the sinusoids must display an at least weak staining reaction

Colon: Endothelial cells of large vessels and stromal cells (e.g. fibroblasts and lymphocytes) must show a strong and distinct cytoplasmic staining reaction, while intraepithelial T-cells must at least display a moderate staining intensity.



Why go with V8 when you can try V9

11 67

GT 9461

Modified table 1

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone V9 IR630	31	Agilent/Dako	27	1	3	0	90%	87%
mAb clone V9 GA630	29	Agilent/Dako	23	2	4	0	86%	79%
mAb clone V9 790-2917	100	Roche/Ventana	21	51	19	9	72%	21%
mAb clone V9 PA0640	7	Leica/Novocastra	5	2	0	0	100%	71%
Total	308		133	96	49	30	-	
Proportion			43%	31%	16%	10%	74%	

Table 4. Proportion of sufficient and optimal results for VIM for the most commonly used RTU IHC systems										
RTU systems	Reco	ommended	Laborator	y modified						
	protoc	ol settings*	protocol settings**							
	Sufficient	Optimal	Sufficient	Optimal						
Leica BOND MAX/III mAb V9 PA0640	3/3	2/3	4/4	3/4						
Dako AS mAb V9 IR630	92% (11/12)	92% (11/12)	88% (15/17)	82% (14/17)						
Dako Omnis mAb V9 GA630	100% (16/16)	100% (16/16)	64% (7/11)	45% (5/11)						
VMS Ultra/XT/GX mAb V9 790-2917	1/1	0/1	72% (71/99)	21% (21/99)						

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.
 ** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered >25%, detection kit – only protocols performed on the specified vendor IHC stainer were included.

"Recommendations from the vendor during run 52 2018: HIER in CC1 for 64 min., 16 min. incubation time in primary Ab and used the biotin-based iView as the detection system (...)" The information provided in the spec sheet of the RTU product was outdated and needed to be revised.

> 100% of the insufficient staining result was a too weak or completely false negative staining reaction of cells and structures expected to be demonstrated. This pattern was observed in 79/79 of the insufficient results.



NQC: HIER CC1 32-64 min + AB 16-32 min = 78% pass-rate

Updated recommendations 2022

d staining protocol for CONFIRM anti-Vimentin (V9) antibody with tion Kit on BenchMark IHC/ISH instruments.

kit – only protocols	Method						
Procedure Type	GX	хт	ULTRA or ULTRA PLUS ^a				
Deparaffinization	Selected	Selected	Selected				
Cell Conditioning (Antigen Unmasking)	CC1, 24 minutes						
Pre-Primary Peroxidase Inhibitor	Selected Selected		Selected				
Antibody (Primary)	16 minutes, 37 °C	16 minutes, 37 °C	16 minutes, 36 °C				
OptiView HQ Linker		8 minutes (default	i)				
OptiView HRP Multimer	1	8 minutes (default	:)				
Counterstain	Hematoxylin II, 4 minutes						
Post Counterstain		Bluing, 4 minutes					



Overview

Marker	Last run	Pass rate/optimal	No. of labs
CD45	Run 59 2020	<mark>94%</mark> /79%	296
PAN-CK	Run 58 2020	<mark>75%</mark> / 52%	326
S100	Run 59 2020	<mark>82%</mark> /48%	299
Vimentin	Run 52 2018	<mark>74%</mark> / 43%	308


What else do you have?

Markers	Control	Last run	Pass rate / Optimal	No. of labs	
СК20	Appendix	62 2021	<mark>94%</mark> / 74%	360	
CK7	Pancreas, appendix	62 2021	<mark>94%</mark> /74%	359	
SATB2	Appendix, testis, tonsil	64 2022	<mark>75%</mark> / 42%	173	
CDX2	Pancreas, tonsil	61 2021	<mark>91%</mark> / 79%	325	
AMACR	Kidney	65 2022	<mark>93%</mark> / 74%	334	
MLA	Skin, low level MLA tumors	60 2020	<mark>88%</mark> /26%	312	
SOX10	Skin, appendix	60 2020	<mark>92%</mark> /67%	250	
Uroplakin	Urethra, tonsil	59 2020*	45% / 21%	66	
Pax8	Kidney, fallowpian tube	64 2022	<mark>52%</mark> /27%	337	
GATA3	Tonsil, uterine cervix	63 2021	<mark>68%</mark> / 41%	320	
Desmin	Appendix, placenta	64 2022	<mark>69%</mark> / 41%	370	
BRAF	Positive and negative tumors	62 2021*	72% / 35%	135	
CD56	Tonsil	64 2022	<mark>72%</mark> /47%	363	
CD31	Liver, tonsil	62 2021	<mark>79%</mark> /56%	342	

*First NordiQC run



When the concept works!



CK20 performance in NordiQC assessments





CK7 and CK20 – you GO!

п	cc 1	
11	Suff. ¹	

able	1.	Antibodies	and	assessment	marks for	CK7, Ru	n 62
------	----	------------	-----	------------	-----------	---------	------

Ready-To-Use antibodies		/endor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
Al along OV TI 12/20				1	0	l	100%	92%
IR619 ³	12 D	Dako/Agilent	11	1	U			
mAb clone OV-TL 12/30,	12 [Dako/Agilent	11	1	0	0	100%	92%
IR619⁴	ŀ	- 1 - 14 - 11-mb	31	1	0	0	100%	97%
mAb clone OV-TL 12/30 , GA619 ³		Dako/Agilent		2	1	0	97%	90%
mAb clone OV-TL 12/30,	30	Dako/Agilent	27			0	100%	17%
GA619*	-	Leica Biosystems	1	5	0			
mab clone RN7,	6		5	6	0	0	100%	-
PA0942 ³	11	Leica Biosystems	5		0	0	100%	69%
mAb clone RN7, PA0942/PA01384			11	5		1	97%	85%
PA0942/PAC		6 Ventana/Roche	86	12	2 2	1		
700-4402	-	01 Ventana/Roche	265	71	1 20	3 1%	1 040/-	5
al clone SPS2			265	% 20%	2,10	T	11 2+10	2
rmAb clone 790-4462⁴	3	359	740	% 50	10	3	3 -	10 820
Total			26	55 7	71 2	1		010
Proportion			86	I	12		0 1000	
Proportion		101 Ventana/Roche 359			2 0			
lotal		101 Ventand		11				
790-4462 ⁴		16 Ventana/Roche						
ITMAb clone SP52, 790-44624		a pipsystems						

		•						Sul	ff. ¹	OR	
		Sement marks for Cl	(20, run	62 nal Good	Borderli	ne l	- -	100	%	84%	6
Table 1. Antibodies and Ready-To-Use antibodies	n	Vendor	16	3	-					85%	2
rmAb clone SP33 790-4431 ³	19	Ventana/Roche	89	14	2		-	98%	0	00,	
rmAb clone SP33 790-4431 ⁴	105	Ventana/Roche		4	-		-	100%	67	78%	
mAb clone Ks20.8 IR/IS777 ³	18	Dako/Agilent	14					94%	7	5%	
mAb clone Ks20.8 I R/IS777 ⁴	16	Dako/Agilent	12	3	1			J -1 70			
mAb clone Ks20.8 GA777 ³	33	Dako/Agilent	31	2	-	-		100%	94	1%	
mAb clone Ks20.8 GA777⁴	27	Dako/Agilent	19	7	1	-	j,	96%	70	%	/
mAb clone Ks20.8 PA0022 ³ mAb clone Ks20.8	5	Leica Biosystems	4	1	-	-	_	000/			
7 40022 ⁴ Total		Leica Biosystems	7	3			1	00%	809	%	
roportion	360		266	72	21	-	10	0%	70%	6	
0tal	360		74%	20%	6%	1					
VP CIOLIC Inc.	10 L	eica Biosystems	266	72 20%	6%	-	∥ 94	%			
5A7774	5 L	eica Biosystems	7	3	21	1		010			
			4	1		-	100	0/0			
					-	-	100°		0,00		
								8	0°/0		


Markers	Control	Last run	Pass rate / Optimal	No. of labs	
СК20	Appendix	62 2021	<mark>94%</mark> / 74%	360 Nord	QC
CK7	Pancreas, appendix	62 2021	<mark>94%</mark> / 74%	359	
SATB2	Appendix, testis, tonsil	64 2022	<mark>75%</mark> /42%	173	
CDX2	Pancreas, tonsil	61 2021	<mark>91%</mark> / 79%	325	
AMACR	Kidney	65 2022	<mark>93%</mark> / 74%	334	
MLA	Skin, low level MLA tumors	60 2020	<mark>88%</mark> / 26%	312	
SOX10	Skin, appendix	60 2020	<mark>92%</mark> / 67%	250	
Uroplakin	Urethra, tonsil	59 2020*	45% / 21%	66	
Pax8	Kidney, fallowpian tube	64 2022	<mark>52%</mark> /27%	337	
GATA3	Tonsil, uterine cervix	63 2021	<mark>68%</mark> /41%	320	
Desmin	Appendix, placenta	64 2022	<mark>69%</mark> /41%	370	
BRAF	Positive and negative tumors	62 2021*	72% / 35%	135	
CD56	Tonsil	64 2012	<mark>72%</mark> /47%	363	
CD31	Liver, tonsil	62 2021	<mark>79%</mark> /56%	342	

*First NordiQC run



Melan A

Run 56 2019 the pass rate was a low 65%. In Run 60 it has increased to 88%. The amount of optimal however was low in both runs 24% and 26% respectively.




MLA performance in NordiQC assessments

Aim and purpose

In previous NordiQC MLA assessments, laboratories using the mAb clone A103 have been assessed on their ability to detect both the specific MLA and the unknown crossreacting protein in steroid hormone producing cells and corresponding tumours, whereas laboratories using other clones have been assessed on their ability to detect MLA only.





60%

						GX / XT / Ultra			
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC1 pH 8.5 + Protease 3	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
mAb clone A103	0/5** (0%)	0/1	6/9 (66%)	-	5/34 (15%)	-	-	7/17 (41%)	0/1
rmAb clone EP43	-	-	5/5 (100%)	-	5/6 (83%)	6/6 (100%)	-	1/1	-



Immunostainer

Type:

Primary antibody

Clone: Producer: Product no. / lot no.: Format: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

Visualization system

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

Immunostainer Type:

Product no. / lot no.:

Epitope retrieval, HIER

Visualization system

Incubation time / temperature:

Heating time at max. temp.:

Maximum heating temp .:

Incubation time linker:

Incubation time polymer:

Incubation temperature:

Primary antibody

Clone:

Producer:

Format:

Device:

Buffer:

Producer:

Leica BOND III

Leica/Novocastra

15 min. / 20°C

PA0233/PA0044 / 66904

On Board / On Machine

Bond Refine / DS9800

Ready-To-Use (prediluted)

A103

20 min.

100°C

Leica

8 min.

8 min.

20°C

Product / no:


Ventana Benchmark Ultra

A103 Ventana Roche 790-2990 / f27660 Ready-To-Use (prediluted) 32 min. / 37°C

On Board / On Machine Ventana Ultra CC1 64 min. 98°C

Ventana OptiView DAB IHC Detection Kit / 760-700 8 min. 8 min. 37°C





Immunostainer

Primary antibody

Product no. / lot no.:

Epitope retrieval, HIER

Visualization system

Producer:

Linker:

Product / no:

Incubation time / temperature:

Heating time at max. temp.:

Maximum heating temp.:

Incubation time polymer:

Incubation temperature:

Type:

Clone:

Format:

Device:

Buffer:

Producer:

Immunostainer Type:

Revision of the second Clone: Producer: Format: Device:

Product no. / lot no.: Incubation time / temperature: Epitope retrieval, HIER

Buffer: Heating time at max. temp.:

Visualization system

Producer: Product / no: Linker: Incubation time linker: Incubation time polymer: Incubation temperature:

Dako Autostainer Link 48 +

A103 Dako IR633/IS633 / 20067423 Ready-To-Use (prediluted) 20 min. / 22°C

PT-link / PT-module Dako TRS High pH (3-1) 20 min. 99°C


Dako EnVision FLEX / K8000/SM802 None 20 min. 22°C

A103 Dako Not Omnis RTU IR633/IS633 / 20079125 Ready-To-Use (prediluted) 20 min. / 32°C

Dako Omnis

On Board / On Machine Dako Omnis Target Retrieval Solution, High pH 30 min. 97°C

Dako Omnis EnVision Flex / GV800/GV823 Mouse LINKER 10 min. 20 min. 32°C





PAX8

PAX8 performance in NordiQC assessments





Number of participants





Pushing in the right direction



Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone BC12*	6 4	Biocare Zytomed Systems	2	4	4	-	60%	20%
mAb clone MRQ-50	25	Cell Marque	-	17	7	1	68%	-
rmAb clone EP298 5*	3 1	Cell Marque Epitomics ⁵	-	1	-	3	-	-
rmAb clone EP331 *	9 6	Cell Marque Epitomics	-	8	6	1	53%	-
rmAb clone SP348 *	105 3 3	Abcam Gennova Spring Bioscience	81	24	4	2	95%	73%
rmAb clone ZR-1 *	3 1 1	Zeta Corporation Gene Tech ImmunoForce	2	1	1	1	60%	40%
pAb, 10336-1-AP	13	Proteintech	-	3	6	4	23%	-
Conc total	199		88	63	34	14	76%	44%
Ready-To-Use antibodies							Suff. ¹	OR. ²
rmAb clone, EP331* 760-6077(VRPS) ³	5	Ventana/Cell Marque	-	-	5	-	-	-
rmAb clone, EP331* 760-6077(LMPS) ⁴	15	Ventana/Cell Marque	-	-	11	4	-	-
mAb clone MRQ-50, 760-4618 (VRPS) ³	3	Ventana/Roche	-	-	-	3	-	-
mAb clone MRQ-50, 760-4618 (LMPS) ⁴	55	Ventana/Roche	-	4	33	18	7%	-
RTU total	138		3	20	76	39	17%	2%
Total	337		91	83	110	53	-	
Proportion			27%	25%	33%	15%	52%	



Not an easy antibody

Table 3. Proportion of optimal results for PAX8 for the most commonly used antibodies as concentrate on the four main IHC systems*

Concentrated antibodies	Dako/Agilent Autostainer		Dako/Agilent Omnis		Ventana/Roche BenchMark GX / XT / Ultra			Leica Biosystems Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC1 pH 8.5 + P3	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
rmAb SP348	4/8 (50%)	-	29/31 (94%)	0/1	45/63 (71%)	3/5 (60%)	0/2	0/1	-
rmAb ZR-1	1/1	-	-	_	0/1		-	0/2	-
mAb BC12	-	-	-	-	-	-	-	2/6 (33%)	-




 Table 5. Overview of the assessment marks for mAb clone MRQ-50 on the four main IHC instruments in runs 62 and 64 (cumulated data for both RTU and concentrate).

MRQ-50 score	Dako/Agilent Autostainer	Dako/Agilent Omnis	Ventana/Roche BenchMark GX / XT / Ultra	Leica Biosystems Bond III / Max
Optimal	-	-	-	-
Good	22	-	12	31
Borderline	4	11	110	3
Poor	-	3	59	-
Total	26	14	181	34
Sufficient %	85%	0%	7%	91%




Kidney





Renal clear cell carcinoma

SP348 ventana



MRQ-50 ventana







Immunostainer Type:

Primary antibody Clone: Producer:

Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

Visualization system

Type:

Clone:

Buffer:

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

Ventana Benchmark Ultra

SP348 Abcam ab227707 / GR3298900-1 Antibody Diluent 1:100 32 min. / 36°C

On Board / On Machine Ventana Ultra CC1 64 min. 100°C

Ventana OptiView DAB IHC Detection Kit / 760-700 8 min. 8 min. 36°C

Immunostainer Primary antibody ZR1 Producer: Product no. / lot no.: Diluent: Dilution factor: 1:25 Incubation time / temperature: Epitope retrieval, HIER Device:

Heating time at max. temp.: Maximum heating temp.:

Visualization system

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

Leica BOND III

Zeta Corportion Z2202 / Z220RT Bond Antibody Diluent 45 min. / 20°C

> On Board / On Machine Leica Bond Epitope Retrieval Solution 2 30 min. 100°C

Leica Bond Refine / DS9800 8 min. 8 min. 20°C

Immunostainer Type:

Primary antibody

Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

/isualization system

Producer: Product / no: Linker Incubation time linker: Incubation time polymer: Incubation temperature:

Abcam ab227707 / GR33234272 Renoir Red Diluent 1:200

Dako Omnis

SP348

On Board / On Machine Dako Omnis Target Retrieval Solution, High pH 30 min. 97°C

Dako Omnis EnVision Flex / GV800/GV823 Rabbit LINKER 10 min. 20 min. 32°C

20 min. / 32°C



Primary antibody

Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

Visualization system

Producer: Product / no: Linker: Incubation time linker: Incubation time polymer: Incubation temperature:

Dako Autostainer Link 48 +

SP348 Gennova 1:100

AP10761CM / . Antibody Diluent 30 min. / 23°C

PT-link / PT-module Dako TRS High pH (3-1) 20 min. 97°C

Dako EnVision FLEX+ / K8002/SM802 Linker. Rabbit 10 min. 20 min.







Immunostainer Type:

23°C

GATA3

No	rdiQC

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone L50-823	88 24 3 3 2 2 1 1	Cell Marque Biocare BD Pharmingen Zytomed Systems Gennova Bio-SB Immunologic Anacrom DBS	31	40	33	24	56%	25%
rmAb clone EP368	5 1	Cell Marque Quartett	4	-	1	1	67%	67%
mAb clone HG3-31	2	Santa Cruz	-	-	-	2	-	-
rmAb clone ZR65	1	Zeta Corporation	-	-	1	-	-	-
Conc total	137		35	40	35	27	55%	26%
Ready-To-Use antibodies							Suff. ¹	OR. ²
mAb clone L50-823 760-4897 ³	56	Ventana/Roche	36	12	8	-	86%	64%
mAb clone L50-823 760-4897 ⁴	67	Ventana/Roche	41	16	7	3	85%	61%
mAb clone L50-823 390M-17,18,10	42	Cell Marque	14	12	13	3	62%	33%
mAb clone L50-823 PM 405AA	12	BioCare Medical	5	3	2	2	67%	42%
mAb clone L50-823 MAD-000632QD	3 1	Master Diagnostica Vitro SA	1	2	1	-	-	-
mAb clone L50-823 CGM-0130	1	Celnovte	-	1	-	-	-	-
mAb clone GATA3/6664 AMB89	1	BioGenex	-	-	-	1	-	-
RTU total	183		97	46	31	9	78%	53%
Total	320		132	86	66	36		
Proportion			41%	27%	21%	11%	68%	

GATA3 performance in NordiQC assessments







Table 4. Summariza	tion of the	^	nt and optimal marks u ction system	using either 2- or 3-layer of 3-layer dete		
Antibodies	n	Sufficient	Optimal	Sufficient	Optimal	-
mAb conc L50-823 Cell Marque	88	36% (4/11)	9% (1/11)	74% (57/77)	36% (28/77)	1:162
mAb conc L50-823 Biocare Medical	24	(0/1)	(0/1)	26% (6/23)	9% (2/23)	1:77
mAb clone RTU L50-823 760-4897* Ventana/Roche	107	53% (18/34)	6% (2/34)	99% (84/85)	88% (75/85)	
mAb clone RTU L50-823 390M-17,18,10 Cell Marque	42	27% (4/15)	13% (2/15)	96% (26/27)	52% (14/27)	
mAb clone RTU L50-823 PM 405AA Biocare Medical	12	(0/2)	(0/2)	80% (8/10)	50% (5/10)	
*Only protocols performed		ded IHC stainer device are included and HIEP time and/or in				


** regardless of the protocol settings applied e.g., HIER time and/or incubation time in the primary Ab (≥ 10 protocols assessed).





Uterine Cervix


The squamous epithelial cells in the basal and intermediate layer of the surface epithelium display a weak to moderate, but distinct nuclear staining reaction, whereas the nuclei of superficial layers and stroma cells are negative.



Tonsil


The vast majority of T helper cells (Th2) display a moderate but distinct nuclear staining reaction, whereas the B-cells are negative.

Trippel negative breast tumor with low level GATA3



Optimal

RTU system 760-4897 (Ventana/Roche), based on the mAb clone L50-823, applying vendor recommended protocol settings and **OptiView** as detection system. A weak to strong nuclear staining reaction of virtually all neoplastic cells are seen.



Insufficient

RTU system 760-4897 (Ventana/Roche), based on the mAb clone L50-823, applying vendor recommended protocol settings and **UltraView** as detection system. The vast majority of neoplastic cells are false negative and only few are weakly positive





Primary antibody

Type:

Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

Visualization system

Type:

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

Leica BOND III

Ventana Benchmark Ultra

390M-16 / 0000052937

On Board / On Machine

L50-823

1:100

Cell Marque

Antibody Diluent

48 min. / 36°C

Ventana CC1

48 min.

100°C

Ventana

8 min.

8 min.

36°C

Primary antibody Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp .: Maximum heating temp.:

Visualization system

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

L50-823 Cell Marque

OptiView DAB IHC Detection Kit / 760-700

390M-16 / 0000091031 **Bond Antibody Diluent** 1:250 15 min. / 21°C

On Board / On Machine Leica Bond Epitope Retrieval Solution 2 20 min. 100°C

Leica Bond Refine / DS9800 8 min. 8 min. 21°C

Type:

Primary antibody

Dako Omnis

Cell Margue

390M-16 / 1602105L

On Board / On Machine

EnVision Flex / GV800/GV823

Dako Autostainer Link 48 +

390M-16 / 0000010688

Antibody Diluent

20 min. / 21°C

L50-823

1:100

30 min.

10 min.

20 min.

L50-823

1:250

20 min.

97°C

Cell Marque

Antibody Diluent

20 min. / 23°C

PT-link / PT-module

Dako TRS High pH (3-1)

21°C

Dako Omnis

Mouse LINKER

97°C

Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp .:

Visualization system

Producer: Product / no: Linker: Incubation time linker: Incubation time polymer: Incubation temperature:

Type:

Primary antibody Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp .:

Visualization system Producer: Product / no:

Incubation time linker:

Incubation time polymer:

Incubation temperature:

Linker:

Dako EnVision FLEX+ / K8002/SM802 Linker, Mouse 15 min. 20 min. 23°C












Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²				
mAb clone D33	79 5 2 2 1 1 1	Dako/Agilent Cell Marque Epredia Monosan Zytomed BioGenex Biolynx Biotech Diagnostic Biosystems	28	45	17	3	78%	30%	500	Desmir	n performa	nce in
mAb clone DE-R-11	15	Leica Biosystems	9	4	2	-	87%	60%		0.4.04		
mAb clone BS21	8 1	Nordic Biosite Optibodies	8	1	-	-	100%	89%		86%	80%	85%
Conc total	122		47	52	20	3	81%	39%	400			
Ready-To-Use antibodies							Suff. ¹	OR. ²	ants			
mAb clone DE-R-11³ 760-2513	1	Ventana/Roche	-	-	1	-	-	-	articip 008 gr			
mAb clone DE-R-11 ⁴ 760-2513	139	Ventana/Roche	75	23	32	9	71%	54%	er of p			
mAb clone D33 IR/IS606 ³	21	Dako/Agilent	3	9	8	1	57%	14%	Number of participants 00 00			
mAb clone D33 IR/IS606⁴	50	Dako/Agilent	2	9	18	21	22%	4%	Z 100			
mAb clone DE-R-11 PA0032 ³	12	Leica Biosystems	11	1	-	-	100%	92%				
mAb clone DE-R-11 PA0032 ⁴	9	Leica Biosystems	7	2	-	_	100%	88%	0	42	119	194
RTU total	248		105	52	59	32	63%	42%		Run 5 2001	Run 21 2007	Run 3 2012
Total	370		152	104	79	35	256				Number	
Proportion			41%	28%	21%	10%	69%					or paru ci






Appendix

The smooth muscle cells of lamina muscularis propria and myofibroblasts lining the epithelial cells show a moderate to strong staining reaction. No background staining is seen.

Placenta

The vast majority of smooth muscle in vessels in the stromal compartment of villi show a moderate to strong cytoplasmic staining reaction. No reaction of the cytotrophoblastic and syncytiotrophoblastic cells in the placenta was seen.





RTU product IR/IS606 D33 on Omnis using Flex+ protocol

Table 3. Proportion of sufficient and optimal results for Desmin for the most commonly used RTU IHC systems

RTU systems		nmended ol settings*	Laboratory modified protocol settings**		
	Sufficient	Optimal	Sufficient	Optimal	
VMS Ultra/XT mAb DE-R-11 760-2513	-	-	70% (97/138)	53% (74/138)	
Dako AS mAb D33 IR/IS606	57% (12/21)	14% (3/21)	100% (6/6)	17% (1/6)	
Leica Bond III/MAX mAb DE-R-11 PA0032	100% (12/12)	92% (11/12)	100% (5/5)	100% (5/5)	
	100% (12/12)	92% (11/12)	100% (5/5)	100% (5/5)	

Table 2. Proportion of optimal results for Desmin for the most commonly used antibodies as concentrate on the four main IHC systems*

and a second

Concentrated antibody	Dako/A Autost	-	Dako/Agilent Omnis		Ventana/Roche BenchMark XT / Ultra		Leica Biosystems Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
mAb clone D33	4/9** (44%)	0/1	0/14	-	9/43 (21%)	-	13/16 (81%)	1/2
mAb clone DE-R-11	_	-	3/5 (60%)	-	2/6 (33%)	-	4/4 (100%)	-
mAb clone BS21	-	-	7/7 (100%)	-	-	-	0/1	-



Table 4. Pass rates of Ventana/Roche RTU DE-R-11 antibody on the Benchmark platform for different epitope retrieval methods.

Pass rate									
	То	tal	HIER		Proteolysis		HIER + proteolysis		
	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	
mAb DE-R-11 760-2513	139	98 (71%)	74	73 (99%)	49	11 (22%)	16	13 (81%)	

BS21 conc. Omnis HIER TRS High

Leiomyosarcoma

DE-R-11 RTU Ventana Protease 1

Table 1. Recommended Staining Protocols for CONFIRM anti-Desmin (DE-R-11)							
Procedure Type	Platform or Method						
	NexES IHC	BenchMark Series					
Deparaffinization	Off Line	Selected					
Cell Conditioning (Antigen Unmasking)	None required	None required					
Enzyme (Protease)	Protease 1, 8 minutes	Protease 1, 8 minutes					
Antibody (Primary)	Approximately 32 minutes, 37° C	Approximately 16 minutes, 37° C					
A/B Block (Biotin Blocking)	Optional	Optional					
Amplify (Amplification)	Optional	Optional					
Counterstain (Hematoxylin)	Hematoxylin II, 2 to 4 minutes	Hematoxylin II, 2 to 4 minutes					
Post Counterstain	Bluing, 2 to 4 minutes	Bluing, 2 to 4 minutes					





Ventana Benchmark Ultra

Primary antibody

Type:

Clone: Producer: Product no. / lot no.: Format: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp .: Maximum heating temp .:

Epitope retrieval, proteolysis

Enzyme: Enzyme producer / no: Incubation time / temp:

Visualization system

Type:

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

Primary antibody Clone: Producer: Product no. / lot no.: Format:

Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp.:

Visualization system

Producer: Product / no: Incubation time linker: Incubation time polymer: Incubation temperature:

DE-R-11 Ventana 760-2513 / H04767 Ready-To-Use (prediluted) 24 min. / 36°C

On Board / On Machine Ventana Ultra CC1 24 min. 100°C

Protease 3 Ventana / 760-2020

Ventana

4 min. / 36°C

OptiView DAB IHC Detection Kit / 760-700 8 min. 8 min. 36°C

Leica BOND III

DE-R-11 Leica PA0032 / 69490 Ready-To-Use (prediluted) 15 min. / 20°C

> On Board / On Machine Leica Bond Epitope Retrieval Solution 2 20 min. 100°C

Leica Bond Refine / DS9800 8 min. 8 min. 20°C

Primary antibody Clone: Producer: Product no. / lot no.: Diluent: Dilution factor: Incubation time / temperature:

Type:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp.: Maximum heating temp .:

Visualization system

Producer: Product / no: Linker: Incubation time linker: Incubation time polymer: Incubation temperature:

Dako Omnis

BS21 Nordic Biosite BSH-7082 / BSH-11u Antibody Diluent 1:50 30 min. / 21°C

On Board / On Machine Dako Omnis Target Retrieval Solution, High pH 30 min. 97°C

Dako Omnis

Primary antibody

Type:

Clone: Producer: Product no. / lot no.: Format: Incubation time / temperature:

Epitope retrieval, HIER

Device: Buffer: Heating time at max. temp .: Maximum heating temp.:

Visualization system

Producer: Product / no: Linker: Incubation time polymer: Incubation temperature:

Dako Autostainer Link 48 +

EnVision Flex / GV800/GV823

Mouse LINKER

10 min.

20 min.

21°C

Dako

None

21°C

20 min.

D33 Dako IR606 / IS606 / 20082709 Ready-To-Use (prediluted) 20 min. / 21°C

PT-link / PT-module Dako TRS High pH (3-1) 20 min. 99°C

EnVision FLEX / K8000/SM802

